{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:32:10Z","timestamp":1793831530688,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41591-025-03875-5","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:03:10Z","timestamp":1755162190000},"page":"3668-3674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-6689","authenticated-orcid":false,"given":"Kari L.","family":"Kendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay L.","family":"Bellasea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":false,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino K.","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-9755","authenticated-orcid":false,"given":"Alexandra","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hyngstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0071-0534","authenticated-orcid":false,"given":"Andrew S.","family":"Brohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Negrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Kasbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C.","family":"Doolittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boban N.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-5329","authenticated-orcid":false,"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Baselga-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia R.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Perez","family":"Garcilazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Vega-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-9143","authenticated-orcid":false,"given":"Jia Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Naser Al-Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6570","authenticated-orcid":false,"given":"Michael C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"3875_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002\u20131014 (2021).","journal-title":"Lancet"},{"key":"3875_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/jdv.17154","volume":"35","author":"TM Hughes","year":"2021","unstructured":"Hughes, T. M. et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J. Eur. Acad. Dermatol. Venereol. 35, 1290\u20131298 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"3875_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/ng.3382","volume":"47","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194\u20131199 (2015).","journal-title":"Nat. Genet."},{"key":"3875_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature25187","volume":"553","author":"Z Eroglu","year":"2018","unstructured":"Eroglu, Z. et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553, 347\u2013350 (2018).","journal-title":"Nature"},{"key":"3875_CR7","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube, J. M. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra137 (2012).","journal-title":"Sci. Transl. Med."},{"key":"3875_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"3875_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"3875_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"3875_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"3875_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccell.2023.03.010","volume":"41","author":"KM Campbell","year":"2023","unstructured":"Campbell, K. M. et al. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell 41, 791\u2013806 (2023).","journal-title":"Cancer Cell"},{"key":"3875_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u02bcs lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"3875_CR16","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542\u20132552 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR17","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3875_CR18","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.18632\/oncotarget.6494","volume":"7","author":"G Goh","year":"2016","unstructured":"Goh, G. et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7, 3403\u20133415 (2016).","journal-title":"Oncotarget"},{"key":"3875_CR19","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1002\/cncr.25148","volume":"116","author":"R Murali","year":"2010","unstructured":"Murali, R. et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 116, 4130\u20134138 (2010).","journal-title":"Cancer"},{"key":"3875_CR20","doi-asserted-by":"publisher","first-page":"e0119716","DOI":"10.1371\/journal.pone.0119716","volume":"10","author":"D Han","year":"2015","unstructured":"Han, D. et al. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS ONE 10, e0119716 (2015).","journal-title":"PLoS ONE"},{"key":"3875_CR21","doi-asserted-by":"publisher","first-page":"113530","DOI":"10.1016\/j.ejca.2024.113530","volume":"199","author":"JR Brahmer","year":"2024","unstructured":"Brahmer, J. R. et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur. J. Cancer 199, 113530 (2024).","journal-title":"Eur. J. Cancer"},{"key":"3875_CR22","doi-asserted-by":"crossref","unstructured":"Posther, K. E. et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann. Surg. Oncol. 13, 728\u2013739 (2006).","DOI":"10.1245\/ASO.2006.03.091"},{"key":"3875_CR23","doi-asserted-by":"crossref","unstructured":"Hughes, T. M. et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J. Eur. Acad. Dermatol. Venereol. 35, 1290\u20131298 (2001).","DOI":"10.1111\/jdv.17154"},{"key":"3875_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper, C. & Pearson, E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404\u2013413 (1934).","journal-title":"Biometrika"},{"key":"3875_CR25","doi-asserted-by":"crossref","unstructured":"Pintilie, M. Competing Risks: A Practical Perspective (John Wiley & Sons, 2006).","DOI":"10.1002\/9780470870709"}],"updated-by":[{"DOI":"10.1038\/s41591-025-03975-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03875-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:26:30Z","timestamp":1770045990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03875-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3875"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03875-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03975-2","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03975-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.K.: institutional research support from Bristol Myers Squibb and trial support from GlaxoSmithKline, Immunocore, Varian Medical Systems and Merck. S.L.B. reports no competing interests. Z.E.: advisory board for Regeneron, Pfizer, Replimune, Incyte, Natera and SunPharma and research funding from Pfizer and Boehringer Ingelheim. S.H.-L.: scientific advisor\/consultant for Amgen, Ascendis, Astellas, Bristol Myers Squibb, Genmab, Endeavor, Immunocore, Merck, Nektar, Neon Therapeutics, Novartis, Regeneron, Replimune, Vaccinex and Xencor and contracted research through affiliated institutions from Astellas, Aulos Bio, BioAtla, Bristol Myers Squibb, Boehringer Ingelheim, Checkmate, Dragonfly, Erasca, F Star, Genentech, Immunocore, Iovance, Kite Pharma, Lyell, Merck, Nektar, Neon Therapeutics, OncoC4, Pfizer, Plexxikon, Vaccinex, Vedanta and Xencor. K.M.C. reports being a shareholder in Geneoscopy LLC and Georgiamune and has received consulting fees from Geneoscopy LLC, PACT Pharma, Tango Therapeutics, Flagship Labs 81 LLC, the Rare Cancer Research Foundation, the Jaime Leandro Foundation, Noetik and Georgiamune. W.E.C. reports no competing interests. D.A.W.: clinical trial support from Orlucent, Inc. and Blueprint Medicines. J.A.P. reports no competing interests. J.A.S. reports no competing interests. G.K.I.: institutional research grants\/contracts from Pfizer, Regneron, Replmune, Bicara, Merck, Georgiamune, Obsidian, Immunocore, Iovance and Xencor; advisory boards for Pfizer, Regeneron, Replimune and Obsidian; and consultant for Pfizer. A.I.: research funding from Merck. J.H.: institutional research grants\/contracts from Merck, Bristol Myers Squibb, Iovance, Lyell, Natera, Skyline and Philogen. A.S.B.: advisory board for Deciphera and research funding from Merck. N.I.K.: advisory board for Regeneron, Merck, Replimune, Immunocore, Iovance Biotherapeutics, Novartis, IO Biotech, MyCareGorithm and HUYABIO International; travel support from Castle Biosciences and Regeneron; data safety monitoring board for Incyte and AstraZeneca; scientific advisory board for T-Knife Therapeutics; study steering committee for Bristol Myers Squibb, Nektar, Regeneron and Replimune; common stock in Bellicum Pharmaceuticals and Amarin; and research funding (to institution) from Bristol Myers Squibb, Merck, Regeneron, Replimune, GlaxoSmithKline, Celgene, Novartis, IDEAYA Biosciences, Modulation Therapeutics and HUYABIO International. J. Markowitz: research support from Morphogenesis, Inc. (now TuHURA Biosciences, Inc.) and Merck. M.M.: advisory boards for Merck and Regeneron. G.N. reports no competing interests. S.K.: speakers\u02bc bureau for Bristol Myers Squibb. G.C.D.: advisory board for Iovance Biotherapeutics. U.S.: consultancy for Astellas, AstraZeneca, Adaptimmune, Exelixis, Gilead, Imvax, Janssen, Pfizer, Seattle Genetics and Sanofi and research funding (to institution) from Janssen, Exelixis and Astellas\/Seattle Genetics. T.R. reports no competing interests. B.N.M. reports no competing interests. E.M. reports no competing interests. I.B.-C. reports no competing interests. C.R.G. reports no competing interests. I.P.G. reports no competing interests. A.V.-C. reports no competing interests. J.M.C. reports no competing interests. N.N.A.-D. reports no competing interests. S.P.P.: honoraria for advisory boards, steering committees, data safety monitoring boards or consulting from Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Ideaya, Immatics, IO Biotech, Merck Sharp & Dohme, Novartis, Obsidian, OncoSec, Pfizer, Replimune, Scancell and TriSalus Life Sciences. E.S.: consulting for DE Shaw Research and advisory board for Mallinckrodt Pharmaceuticals. J. Moon reports no competing interests. M.C.W. reports no competing interests. A.R. has received honoraria for consulting for Amgen, Bristol Myers Squibb, Merck, Novartis and Roche-Genentech; is or has been a member of the scientific advisory board and holds stock in Appia, Apricity, Arcus, Compugen, CytomX, ImaginAb, ImmPact, Inspirna, Kite-Gilead, Larkspur, Lyell, Lutris, MapKure, Merus, Synthekine and Tango; and has received research funding from Agilent Technologies and from Bristol Myers Squibb through Stand Up to Cancer (SU2C) and patent royalties from Arsenal Bio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}